These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy. Dhawale TM; Johnson PC; Gaballa MR; Nelson AM; Lavoie MW; Boateng KY; Greydanus C; Frigault MJ; El-Jawahri A Cancer; 2023 Feb; 129(3):441-449. PubMed ID: 36457279 [TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479 [TBL] [Abstract][Full Text] [Related]
4. Quality of Life and Prognostic Awareness in Caregivers of Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Barata A; Dhawale T; Newcomb RA; Amonoo HL; Nelson AM; Yang D; Karpinski K; Holmbeck K; Farnam E; Frigault M; Johnson PC; El-Jawahri A Transplant Cell Ther; 2024 Apr; 30(4):452.e1-452.e11. PubMed ID: 38242441 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338 [TBL] [Abstract][Full Text] [Related]
7. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347 [TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Kamal M; Joseph J; Greenbaum U; Hicklen R; Kebriaei P; Srour SA; Wang XS Transplant Cell Ther; 2021 May; 27(5):390.e1-390.e7. PubMed ID: 33965176 [TBL] [Abstract][Full Text] [Related]
10. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732 [TBL] [Abstract][Full Text] [Related]
11. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. El-Jawahri AR; Vandusen HB; Traeger LN; Fishbein JN; Keenan T; Gallagher ER; Greer JA; Pirl WF; Jackson VA; Spitzer TR; Chen YB; Temel JS Cancer; 2016 Mar; 122(5):806-12. PubMed ID: 26650840 [TBL] [Abstract][Full Text] [Related]
12. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy. Barata A; Hoogland AI; Hyland KA; Otto AK; Kommalapati A; Jayani RV; Irizarry-Arroyo N; Collier A; Rodriguez Y; Welniak TL; Booth-Jones M; Logue J; Small BJ; Jain MD; Reblin M; Locke FL; Jim HSL Psychooncology; 2021 Aug; 30(8):1294-1301. PubMed ID: 33739548 [TBL] [Abstract][Full Text] [Related]
13. Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. Hoogland AI; Barata A; Logue J; Kommalapati A; Hyland KA; Nelson AM; Eisel SL; Small BJ; James BW; Christy SM; Bulls HW; Booth-Jones M; Jayani RV; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL Transplant Cell Ther; 2022 Jun; 28(6):305.e1-305.e9. PubMed ID: 35378330 [TBL] [Abstract][Full Text] [Related]
14. Parent Psychological Distress Is Associated with Symptom Burden and Health-Related Quality of Life in Children and Adolescents Undergoing Stem Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy. Ward J; Smith J; Powers K; Hellsten M; Murray P Transplant Cell Ther; 2023 Jul; 29(7):462.e1-462.e9. PubMed ID: 37086850 [TBL] [Abstract][Full Text] [Related]
15. Current status of CAR-T cell therapy for pediatric hematologic malignancies. Hiramatsu H Int J Clin Oncol; 2023 Jun; 28(6):729-735. PubMed ID: 37154980 [TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090 [TBL] [Abstract][Full Text] [Related]
17. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Wang XS; Srour SA; Mendoza T; Whisenant M; Subbiah I; Gonzalez E; Kamal M; Shen SE; Cleeland C; Kebriaei P; Rezvani K; Neelapu S; Ahmed S; Shpall E Br J Haematol; 2023 May; 201(4):738-746. PubMed ID: 36733986 [TBL] [Abstract][Full Text] [Related]
18. Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study. Dai H; Xu S; Han J; Li Z; Cao J; Hu T; Li H; Wei J; Dou X; Zhou F; Zheng J J Affect Disord; 2021 May; 286():33-39. PubMed ID: 33676261 [TBL] [Abstract][Full Text] [Related]